Drug intelligence / Profile preview

recombinant human papillomavirus bivalent (types 16 and 18) vaccine

Development stage: Unknown
Lead developer: GSK
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

This recombinant human papillomavirus bivalent vaccine targets types 16 and 18 of the Human Papillomavirus. It is designed to evaluate its safety and immunogenicity in healthy females aged 9-45 years. The vaccine is administered via a three-dose schedule (0, 2, 6 months) and aims to induce an immune response, specifically neutralizing antibodies, against HPV types 16 and 18. The recombinant proteins are produced in yeast.

Beyond the preview

Go deeper on recombinant human papillomavirus bivalent (types 16 and 18) vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on recombinant human papillomavirus bivalent (types 16 and 18) vaccine.

Explore the full profile